Quoin Pharmaceuticals Ltd., a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company intends to release its 2022 fourth quarter and year-end financial results after the market closes on Wednesday, March 8, 2023.
Latest News
Company continues to advance QRX003 in late-stage clinical trials in Netherton Syndrome patients Regulatory milestone provides 10 years of market exclusivity in Europe upon approval ASHBURN, Va. — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on rare and orphan diseases,...
ASHBURN, Va. — Quoin Pharmaceuticals Ltd., a specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has received U.S. Food and Drug Administration (FDA) clearance to implement a number of protocol amendments to its two ongoing clinical trials for QRX003, which is being developed as a...
Study CL-QRX003-002 will test whole-body application of QRX003 in conjunction with off-label systemic therapy in approximately 12-15 subjects. Study CL-QRX003-002 complements first whole-body pivotal study, CL-QRX003-003, being led by Dr. Amy Paller at Northwestern University and supported by up to six international sites that are expected to open, where subjects...
ASHBURN, Va. — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) , a specialty pharmaceutical company focused on rare and orphan diseases, today announced clearance from the U.S. Food and Drug Administration (FDA) to recruit teen subjects aged 14 years and older into its two ongoing clinical trials for QRX003, which is being...
ASHBURN, Va. — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a specialty pharmaceutical company exclusively focused on the development and commercialization of innovative therapies that treat rare and orphan diseases, today announced it has filed U.S. and International patent applications for a novel combination product as a potential treatment of Netherton Syndrome....
NANTONG and SUZHOU, China — Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to RAG-18, one of the company’s lead saRNA product candidates. This designation follows the recent Rare Pediatric Disease...
NANTONG, China — Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced the successful dosing of the first patient in its investigator-initiated trial (IIT) of RAG-18 at Peking Union Medical College Hospital (PUMCH) in Beijing. This important milestone represents a significant step forward in developing new therapies...
Keira Mathewson is a very cute little girl, two months shy of her second birthday. She also has a brain disease that slows her development, reduces her movement and affects her speech. Keira, who lives with her parents Julie Lewis and Michael Mathewson at Brassall, will be one of the...
Reston, VA — Radioguided surgery can detect and remove metastatic pelvic lymph nodes in patients newly diagnosed with prostate cancer, according to research published in the March issue of The Journal of Nuclear Medicine. Targeting the prostate-specific membrane antigen (PSMA), which is overexpressed in most prostate cancer patients, radioguided surgery can improve...